CuraCell granted approval for trial of new therapy for metastatic cancers

August 13, 2025
Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …

eye1

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025
Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …

Atelerix appoints new chair and non-executive director to drive global expansion

August 13, 2025
Biotech/start-up, Sales and Marketing Atelerix, Corporate, non-executive director

UK-based biotech company, Atelerix, has appointed Sunil Shah as chair of the board and Catherine Elton as non-executive director as …

handshake-1910702_960_720

Sartorius Stedim Biotech partners with Nanotein Technologies to develop cell therapy manufacturing

August 12, 2025
Mergers and Acquisitions Corporate, Nanotein Technologies, Sartorius Stedim Biotech, cell therapy, gene therapy

Sartorius Stedim Biotech has partnered with Nanotein Technologies to expand access to immune cell activation reagents for cell therapy manufacturing. …

Enzymatica appoints Sana Alajmovic as new CEO

August 12, 2025
Research and Development Corporate, Enzymatica, Infections and infestations

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …

Sanner appoints new CEO to drive CDMO strategy

August 11, 2025
Contract Manufacturing, Manufacturing and Production CEO, Corporate, Sanner, contract development and manufacturing organisation

German packaging solutions company, Sanner, has announced a significant leadership change as it advances its transformation into a contract development …

640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025
Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisiโ€™s idebenone (Raxone) within its …

ARTBIO expands board and establishes technical advisory board

August 11, 2025
Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …

pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025
Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron โ€“ a …

Horus Pharma expands distribution in North Africa and the Middle East

August 8, 2025
Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement

Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …

Aragen appoints Aniel Khubchandani as CEO of development and manufacturing solutions division

August 8, 2025
Manufacturing Services, Manufacturing and Production Aragen Life Sciences, CEO, Corporate, development and manufacturing solutions, manufacturing services

Aragen Life Sciences, based in Hyderabad, India, has appointed Aniel Khubchandani as CEO of its development and manufacturing solutions (DMS) …

drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025
Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025
Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanomeโ€™s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …

computer_doctor

Cognizant launches tool to support secure AI integration in healthcare platforms

August 7, 2025
Business Services, Technical Consultancy Cognizant, Devices, healthcare software

US tech solutions company, Cognizant, has launched TriZetto AI Gateway, a new tool designed to embed generative AI functions across …

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025
Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

MedaSystems appoints Anton White as vice president of growth

August 6, 2025
Business Services Corporate, MedaSystems, vice president of growth

US software solutions company, MedaSystems, has named Anton White as vice president of growth to lead global go-to-market strategy and …

lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025
Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

The Gateway to Local Adoption Series

Latest content